Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations

Genes Chromosomes and Cancer

Volumn 29, Issue 2, 2000, Pages 96-105

  Ahuja, Harish G ^a   Felix, Carolyn A ^b   Aplan, Peter D ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GENE PRODUCT; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CHROMOSOME 11P; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; FEMALE; GENE; GENE REARRANGEMENT; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 20; CLONING, MOLECULAR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; TRANSLOCATION, GENETIC;

EID: 0033847847     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1013>3.0.CO;2-T     Document Type: Article

References (38)

1. Ahuja HG, Felix CA, Aplan PD. 1999. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome (t-MDS) results in a NUP98-TOP1 fusion. Blood 94:3258-3261.
2. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. 1996. Site-specific cleavage within the ML1. breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87:2649-2656.
3. Arai Y, Hosoda F, Kobayashi H, Kyoko A, Hayashi Y, Nanao K, Kaneko Y, Ohki M. 1997. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene NUP98 with the putative RNA helicase gene DDX10. Blood 89:3936-3944.
4. Atlas M, Head D, Behm F, Schmidt E, Zeleznik-Le NJ, Roe BA, Burian D, Domer PH. 1998. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia 12: 1895-1902.
5. Borde V, Duguet M. 1998. The mapping of DNA topoisomerase sites in vivo: a tool to enlighten the functions of topoisomerases. Biochimie 80:223-233.
6. Borrow J, Shearman AM, Stanton Jr VP, Becher R, Collins T, Williams AJ, Dube I, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley J, Houseman DE. 1996. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 to class I homeoprotein HOXA9. Nat Genet 12:159-167.
7. Dissing M, Le Beau MM, Pedersen-Bjergaard J. 1998. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 16:1890-1896.
8. Domer PU, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. 1995. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 9:1305-1312.
9. Felix CA. 1998. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400:233-255.
10. Felix CA, Hosler MR, Winnick NJ, Materson M, Wilson AE, Lange BJ. 1995a. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85:3250-3256.
11. Felix CA, Lange BJ, Hosler MR, Fertala J, Björnsti MA. 1995b. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 55:4287-4292.
12. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NKV, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. 1998. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95:13176-13181.
13. Hoffman L, Möller P, Pedersen-Bjergaard J. Waage A, Pedersen M, Hirsh FR. 1995. Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting topoisomerase II. A report of two cases and a review of the literature. Ann Oncol 6:781-788.
14. Hussey DJ. Nicola M, Moore S, Peters GB, Dobrovic A. 1999. The t(4;11)(q21;p15) translocation fuses the NUP98 and RAPIGDSI genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 94:2072-2079.
15. Karp JE, Smith MA. 1997. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol 24:103-113.
16. Kas E, Laemmeli UK. 1992. In vivo topoisomerase II cleavage of the Drosophila histone and satellite II repeats: DNA sequences and structural characteristics. EMBO J 11:705-716.
17. Kunre N, Yang GC, Dolberg MN, Sundarp R, Knippers R, Ritcher A. 1991. Structure of the human type I DNA topoisomerase gene. J Biol Chem 266:9610-9616.
18. Larson RA, Le Beau MM, Ratin MJ, Rowley JD. 1992. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood 79:1892-1893.
19. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough PR, Golomb HM, Rowley JD. 1986. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute non-lymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes 5 and 7. J Clin Oncol 4:325-345.
20. Look AT. 1998. Genes altered by chromosomal translocations in leukemias and lymphomas. In: Kinzler K, Vogelstein B, editors. The genetic basis of human cancer. New York: McGraw-Hill. p 109-141.
21. Megonigal MD, Rappaport EF, Jones DH, Kim CS, Nowell PC, Lange BJ, Felix CA. 1997. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci USA 94:11583-11588.
22. Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SG, Willman CL, Chen IN, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD. 1996. Fusion of the nucleoporin gene NUP98 to HOXA9 by chromosomal translocation t(7;11)(p15;p15) in human myeloid leukemia. Nat Genet 12:154-158.
23. Nakamura T, Yamazaki Y, Hatano Y, Miura I. 1999. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood 94:741-747.
24. Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J, Kalwinski DK, Dahl GV, Murphy SB, Crist WM, Williams DL. 1989. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. NEJM 321:136-142.
25. Radu A, Moore MS, Blobel G. 1995. The peptide repeat domain of nucleopotin NUP98 functions as a docking site in transport across the nuclear pore complex. Cell 81:215-222.
26. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. 1998. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 58:4269-4273.
27. Ripley LS. 1994. Deletion and duplication sequences induced in CHO cells by Teniposide (VM-26), a topoisomerase-II targeting drug, can be explained by processing of DNA nicks produced by the drug-topoisomerase interaction. Mutat Res 312:67-78.
28. Spitzner JR, Muller MT. 1988. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 16:5533-5556.
29. Stanulla M, Wang J, Chervinsky DS, Thandla S, Aplan PD. 1997. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 17:4070-4079.
30. Stanulla M, Schunemann HJ, Thandla S, Brecher ML, Aplan PD. 1998. Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukemia patients. J Clin Pathol 51:85-89.
31. Stark B, Jeison M, Shohat M, Goshen Y, Vogel R, Cohen IJ, Yaniv I, Kaplinsky G, Zaizov R. 1994. Involvement of 11p15 and 3q21q26 in therapy-related myeloid leukemia (t-ML) in children. Case reports and review of the literature. Cancer Genet Cytogenet 75:11-22.
32. Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. 1998 An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 92:3793-3803.
33. Strissel Broeker PL, Gill Super H, Thirman MJ, Pomykala H, Yonebashi Y, Tanabe S, Zeleznik-Le N, Rowley JD. 1996. Distribution of 1 Iq23 breakpoints within the MLL breakpoint cluster region in de novo acute myeloid leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II binding sites. Blood 87:1912-1922.
34. Udvardy A, Schedl P. 1991. Chromatin structure, not DNA sequence specificity is the primary determinant of topoisomerase II sites of action in vivo. Mol Cell Biol 11:4973-4984.
35. Wang JC. 1996. DNA topoisomerases. Annu Rev Biochem 65:635-692.
36. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita Jr VT. 1988. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 71:403-414.
37. Xue Y, Guo Y, Xie X. 1997. Translocation t(7;11)(p15;p15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Leuk Res 21: 107-109.
38. Zhou R-H, Wang P, Zon Y, Jackson-Cooke CK, Povirk LF. 1997. A precise interchromosomal reciprocal exchange between hot-spots for cleavable complex formation by topoisomerase II in Amsacrine-treated Chinese hamster ovary cells. Cancer Res 57:4699-4702.